Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant
临床前开发一种核靶向生物制剂,可安全地增加干细胞体内扩增,以加速化疗和骨髓移植后中性粒细胞减少症的恢复
基本信息
- 批准号:10685290
- 负责人:
- 金额:$ 23.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-17 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:ANXA5 geneAccelerationAdverse effectsAdverse eventAftercareApoptosisApoptoticBiologicalBiological AssayBloodBone MarrowBone Marrow DiseasesBone Marrow TransplantationCD34 geneCell NucleusCell TransplantationCellsChemotherapy and/or radiationChimeric ProteinsChimerismClinicClinicalClinical TrialsComplexConsumptionDataDiseaseDoseDyesEngraftmentExcisionExploratory/Developmental Grants Phase IIExposure toFemaleFluorescence MicroscopyFutureGelGeneticGoalsHalf-LifeHela CellsHematopoieticHematopoietic NeoplasmsHematopoietic Stem Cell TransplantationHematopoietic stem cellsHomeodomain ProteinsHospitalizationHourHumanImmune systemImmunodeficient MouseIn VitroInfectionInflammatoryInpatientsIntravenous infusion proceduresLeadLegal patentLibrariesLifeMalignant Bone Marrow NeoplasmMeasuresMethodologyMethodsModelingMonitorMucositisMusMyelogenousMyeloproliferative diseaseNecrosisNeutropeniaNuclearPatient-Focused OutcomesPatientsPenetrationPeptidesPharmaceutical PreparationsPhasePredispositionProliferatingProteinsRecoveryResistanceRiskSafetyScanningSiteSourceStainsSystemTherapeuticTimeToxic effectToxicologyTransplant RecipientsTransplantationTransplantation Conditioningcandidate identificationcandidate selectionchemotherapyclinical investigationcomparison controlconditioningcostcytotoxicityefficacy evaluationefficacy studyexperiencehematopoietic stem cell expansionhigh riskimprovedin vivoinfection riskinnovationlead candidatemalemanmanufacturemutantnoveloverexpressionperipheral bloodpost-transplantpre-clinicalpreclinical developmentreconstitutionsafety studyscreeningstem cell expansionstem cell functiontranscription factoruptake
项目摘要
Hematopoietic stem cell (HSC) transplants (HSCTs) are considered a potentially curative option for patients with
certain cancers of the blood and bone marrow and over 20,000 HSCTs are performed in the US each year.
However, HSCTs are associated with high risk due to the required removal of diseased bone marrow before
transplantation. Until the transplanted cells engraft and proliferate enough to reconstitute the patient’s immune
system, the patient is considered neutropenic during which they are highly susceptible to infection. In addition to
the potentially life-threatening physical risk to the patient, neutropenia necessitates long hospitalization time that
can in part drives the expensive cost of HSCTs ranging up to $400,000 in the US. A current strategy in clinical
trials is to transplant larger pools of donor HSCs to shorten the neutropenic phase. However, these approaches
all rely on ex vivo culturing of donor cells that depend on imperfect man-made culture systems that may disrupt
the proper function of the stem cells and can be prohibitively expensive. Ship of Theseus’ innovative solution is
a drug that will be used for a brief, one-time exposure to donor cells prior to transplantation that improves
expansion in vivo. Our drug is a patented mutant of nuclear transcription factor, Homeobox protein B4
(HOXB4(m)), which promotes HSC expansion without differentiation. HOXB4(m) has improved degradation
resistance, which enables us to overcome several shortcomings of HOXB4 (e.g., short protein half-life and
myeloproliferative disorders associated with genetic overexpression). By elongating its intracellular half-life,
HOXB4(m) is practical for clinical use while potentially avoiding adverse effects induced by constitutive
overexpression. Early preclinical data indicating treating cells with HOXB4(m) can expand all major lineages of
HSCs while maintaining multipotency. However, current delivery of HOXB4(m) is limited by its ability to penetrate
cells and localize in the nucleus, the site of its bioactivity.
The goal of this R61/R33 proposal is to improve efficiency and safety of HOXB4(m) by improving its nuclear
delivery. This will be accomplished through the execution of 3 aims. In Aim 1 (R61), we will perform a library
screen to identify optimal combinations of cell penetrating peptide and nuclear targeting motifs for HOXB4(m)
nuclear localization. In Aim 2 (R33), we will assess in vitro efficacy of the top candidates to select a lead
candidate. In Aim 3 (R33), we will demonstrate long-term hematopoietic reconstitution without adverse effects
or GVHD of our lead candidate in vivo in a mouse HSCT study. Successful completion of this R61/R33 program
will demonstrate feasibility of an improved HOXB4(m) candidate that maintains efficacy at lower concentrations
and briefer exposure periods. This project will provide the necessary data to support future extensive in vivo
efficacy and safety studies necessary for an IND submission. With HOXB4(m), we can circumvent the original
hurdles of HOXB4 and improve expansion in vivo to benefit HSCT patients by shortening the neutropenic phase
to reduce infection, hospitalization time, and cost.
造血干细胞移植(HSCT)被认为是治疗慢性粒细胞白血病患者的一种潜在选择。
在美国,每年有超过20,000例血液和骨髓癌以及超过20,000例造血干细胞移植。
然而,造血干细胞移植的风险很高,因为在移植之前需要切除患病的骨髓。
移植。直到移植的细胞植入并增殖到足以重建患者的免疫系统
系统中,患者被认为是中性粒细胞减少症,在此期间他们极易受到感染。除了……之外
中性粒细胞减少症可能危及患者的生命,因此需要较长的住院时间。
在美国,CAN在一定程度上推动了HSCT的昂贵成本,最高可达40万美元。当前临床上的一种策略
试验的目的是移植更多的捐赠者HSCs,以缩短中性粒细胞减少期。然而,这些方法
所有这些都依赖于捐赠者细胞的体外培养,这些细胞依赖于不完善的人工培养系统,这可能会破坏
干细胞的正常功能,而且可能昂贵得令人望而却步。特修斯之船的创新解决方案是
一种在移植前用于短暂、一次性接触供体细胞的药物,可改善
体内扩张。我们的药物是核转录因子同源框蛋白B4的专利突变体
(HOXB4(M)),促进无分化的HSC扩张。HOXB4(M)改善了降解性
抗性,这使我们能够克服HOXB4的几个缺点(例如,蛋白质半衰期短和
与基因过度表达相关的骨髓增殖性疾病)。通过延长其细胞内的半衰期,
HOXB4(M)可用于临床,同时潜在地避免由成分引起的不良反应
过度表达。早期临床前数据表明,用HOXB4(M)处理细胞可以扩大所有主要的
造血干细胞,同时保持多能性。然而,目前HOXB4(M)的递送受到其渗透能力的限制
细胞,并定位于其生物活性所在的细胞核。
R61/R33提案的目标是通过改进HOXB4(M)的核性能来提高其效率和安全性
送货。这将通过执行3个目标来实现。在目标1(R61)中,我们将执行库
HOXB4(M)细胞穿透肽和核靶向基序最佳组合的筛选
核本地化。在目标2(R33)中,我们将评估最佳候选者的体外效率以选择一条线索
候选人。在目标3(R33)中,我们将演示长期的造血重建,没有不良反应
在小鼠造血干细胞移植研究中,我们的主要候选者体内的GVHD。成功完成此R61/R33计划
将展示改进的HOXB4(M)候选药物的可行性,该候选药物在较低浓度下保持效力
以及更短的曝光期。该项目将提供必要的数据,以支持未来在体内的广泛应用
提交IND申请所需的有效性和安全性研究。使用HOXB4(M),我们可以绕过原始的
HOXB4的障碍和通过缩短中性粒细胞减少期改善体内扩张使HSCT患者受益
以减少感染、住院时间和成本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy A Elser其他文献
Jeremy A Elser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy A Elser', 18)}}的其他基金
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant
临床前开发一种核靶向生物制剂,可安全地增加干细胞体内扩增,以加速化疗和骨髓移植后中性粒细胞减少症的恢复
- 批准号:
10448536 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant
干细胞体内扩增的刺激物,可加速化疗和干细胞移植继发的中性粒细胞减少症的恢复
- 批准号:
10324724 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
相似海外基金
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
- 批准号:
23H01186 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)